Compare FPI & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | DNA |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 520.6M |
| IPO Year | 2013 | 2020 |
| Metric | FPI | DNA |
|---|---|---|
| Price | $9.78 | $6.92 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 397.2K | ★ 994.2K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | N/A | ★ 46.49 |
| EPS | ★ 0.08 | N/A |
| Revenue | $52,178,000.00 | ★ $170,155,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $124.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.21 | $5.37 |
| 52 Week High | $13.23 | $17.58 |
| Indicator | FPI | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 36.79 |
| Support Level | $9.39 | $6.21 |
| Resistance Level | $9.96 | $7.38 |
| Average True Range (ATR) | 0.20 | 0.55 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 74.10 | 10.56 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.